首页> 外文期刊>The Pediatric infectious disease journal >Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
【24h】

Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.

机译:日本川崎病患者对初始静脉免疫球蛋白治疗无反应的潜在危险因素分析。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Some Kawasaki disease (KD) patients do not respond to initial treatment with intravenous immunoglobulin (IVIG). The purpose of this study was to determine potential risk factors associated with IVIG nonresponse among KD patients in Japan. METHODS: Data were obtained from questionnaires used for the 18th nationwide KD survey of patients who visited hospitals in Japan from 2003 through 2004. Data for patients who met the case definition for KD and received 2 g/kg single infusion IVIG as the initial treatment within 10 days of illness were analyzed. IVIG nonresponders were defined as patients who needed secondary treatment after initial IVIG administration. RESULTS: Among 15,940 KD patients in Japan during 2003-2004, 6330 patients received 2 g/kg single infusion IVIG within 10 days of illness onset. IVIG nonresponders accounted for 20.3% of them (n = 1286). Male sex [odds ratio (OR), 1.21, 95% confidence interval (CI), 1.06-1.37], receipt of the initial IVIG before the fifth day of illness (OR: 1.89, 95% CI: 1.66-2.15), and having recurrent KD (OR: 1.38, 95% CI: 1.00-1.90) were significantly associated with IVIG nonresponse. In addition, IVIG nonresponders had significantly higher risks for coronary artery aneurysms (OR: 10.38, 95% CI: 6.98-15.45) or giant coronary artery aneurysms (OR: 54.06, 95% CI: 12.84-227.65). CONCLUSIONS: Physicians should consider potential IVIG nonresponse among recurrent KD patients or KD patients diagnosed and treated before the fifth day of illness, particularly if they are boys and have laboratory values associated with nonresponse such as low platelet count, and elevated alanine aminotransferase and C-reactive protein. Some of these patients may benefit from administration of the alternative secondary treatment early during the illness along with the initial IVIG treatment.
机译:背景:一些川崎病(KD)患者对静脉注射免疫球蛋白(IVIG)的初始治疗无反应。这项研究的目的是确定日本KD患者与IVIG无反应相关的潜在危险因素。方法:数据来自于2003年至2004年在日本医院进行的第18次全国KD调查中使用的问卷。符合KD病例定义并接受2 g / kg单次输注IVIG作为初始治疗的患者的数据分析了10天的疾病。 IVIG无反应者定义为初次IVIG给药后需要二次治疗的患者。结果:在2003年至2004年的日本15940名KD患者中,有6330名患者在发病10天之内接受了2 g / kg单次输注IVIG。 IVIG无反应者占其中的20.3%(n = 1286)。男性[比值(OR),1.21,95%置信区间(CI),1.06-1.37],在患病第五天之前接受初次IVIG(OR:1.89,95%CI:1.66-2.15),以及复发性KD(OR:1.38,95%CI:1.00-1.90)与IVIG无反应显着相关。此外,IVIG无反应者发生冠状动脉瘤(OR:10.38,95%CI:6.98-15.45)或巨大冠状动脉瘤(OR:54.06,95%CI:12.84-227.65)的风险明显更高。结论:医师应考虑在患病第五天之前复发的KD患者或确诊和治疗的KD患者中潜在的IVIG无反应,特别是如果他们是男孩并且具有与无反应相关的实验室检查值,例如血小板计数低,丙氨酸转氨酶和C-升高反应蛋白。这些患者中的一些患者可能会在疾病早期以及最初的IVIG治疗期间受益于替代性二级治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号